Core Insights - Fennec Pharmaceuticals Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:00 p.m. ET, available via webcast [1][2] Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity in cancer patients [3] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3] Licensing and Commercialization - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently commercially available in the U.K. and Germany [4] Regulatory Status and Market Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents protecting PEDMARK until 2039 in both the U.S. and internationally [5]

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company’s previously announced underwritten public offering in the United States and concurrent private ...

Core Points - Fennec Pharmaceuticals Inc. has closed a non-brokered offering of common shares in Canada at a price of US$7.50 per share, raising aggregate gross proceeds of US$5,025,000 [1][2] Group 1: Offering Details - The offering was made to prospective purchasers in Canada (excluding Quebec) under the listed issuer financing exemption, and the common shares are not subject to a hold period under Canadian securities laws [2][4] - The offering document related to this transaction can be accessed on the Company's profile at www.sedarplus.com and www.fennecpharma.com [3] Group 2: Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with its primary product being PEDMARK, which received FDA approval in September 2022 and European Commission approval in June 2023 [6][8] - PEDMARQSI, the brand name for PEDMARK in the U.K., received approval in October 2023, and the product is now commercially available in the U.K. and Germany following an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. [7][8] Group 3: Regulatory and Market Position - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [8] - Fennec holds patents for PEDMARK that extend until 2039 in both the U.S. and internationally, enhancing its competitive position in the market [8]

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters’ option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec’s total gross proceeds from the offering (before deducting the underw ...

Core Viewpoint - Fennec Pharmaceuticals Inc. is initiating a non-brokered offering of common shares in Canada at a price of US$7.50 per share, aiming for gross proceeds of up to US$5,025,000, with the offering expected to close on November 17, 2025, subject to customary closing conditions [1][2]. Offering Details - The offering targets prospective purchasers in Canada (excluding Quebec) under the listed issuer financing exemption, and the shares will not be subject to a hold period under Canadian securities laws [2][4]. - There are no guarantees regarding the completion of the offering or the total gross proceeds raised [2]. Company Background - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its product PEDMARK approved by the FDA in September 2022 and by the European Commission in June 2023 [6][8]. - The company has an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [7]. Regulatory and Market Position - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has Pediatric Use Marketing Authorization in Europe, providing significant market protection [8]. - Fennec holds patents for PEDMARK that extend until 2039 in both the U.S. and internationally, enhancing its competitive position in the market [8].

Core Viewpoint - Fennec Pharmaceuticals Inc. has announced a public offering of 4,666,667 common shares priced at $7.50 per share, aiming to raise approximately $35 million in gross proceeds before expenses [1][2] Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 700,000 common shares under the same terms [1] - The expected closing date for the offering is November 17, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used to repurchase and redeem certain indebtedness, with any remaining funds allocated for working capital and general corporate purposes [2] Group 3: Company Background - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its product PEDMARK approved by the FDA in September 2022 and by the European Commission in June 2023 [5][6] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand [6] - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [7]

Company Performance - Adherex Technologies Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.21 per share a year ago, representing an earnings surprise of +75.00% [1] - The company posted revenues of $12.46 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 11.62%, and showing significant growth from year-ago revenues of $6.97 million [2] - Over the last four quarters, Adherex Technologies has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Adherex Technologies shares have increased approximately 23.1% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.02 on revenues of $13.42 million, and for the current fiscal year, it is -$0.25 on revenues of $42.99 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Fennec Pharmaceuticals Inc. is initiating an underwritten public offering of its common shares, with plans to use the proceeds for debt repayment and general corporate purposes [1][2]. Group 1: Offering Details - The company intends to offer common shares and grant underwriters a 30-day option to purchase an additional 15% of the shares sold in the offering [1]. - The offering is being conducted under a registration statement that has been declared effective by the SEC, with a preliminary prospectus supplement to be filed [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to repurchase certain indebtedness, with any remaining funds allocated for working capital and general corporate purposes [2]. Group 3: Company Background - Fennec Pharmaceuticals focuses on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, primarily through its product PEDMARK, which has received various regulatory approvals [5][6]. - PEDMARK has Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [7].

Financial Performance - PEDMARK® recorded net product sales of $12,462,000 in Q3 2025, a 78% increase from $6,974,000 in Q3 2024, driven by increased market penetration and focus on the adolescent and young adult population [163]. - Net product sales for the first three quarters of 2025 reached $30,865, a 42.5% increase from $21,655 in 2024, driven by increased market penetration and focus on the adolescent and young adult population [167]. - Total revenue for the nine months ended September 30, 2025, was $30,865, down from $39,613 in 2024, reflecting a decrease of $8,748 [165]. - The net loss for the nine months ended September 30, 2025, was $4,954, compared to a net income of $1,549 in 2024, representing a decline of $6,503 [165]. Expenses - Selling and marketing expenses rose to $5,210,000 in Q3 2025 from $4,601,000 in Q3 2024, reflecting enhanced commercial and marketing efforts in the U.S. [163]. - General and administrative expenses increased by $631,000 in Q3 2025 compared to the same period in 2024 [164]. - Operating expenses totaled $34,593 for the nine months ended September 30, 2025, a decrease of $1,518 compared to $36,111 in 2024 [165]. - Selling and marketing expenses decreased to $12,510 in 2025 from $14,482 in 2024, primarily due to the completion of European pre-commercial activities [167]. Cash Flow and Liabilities - Cash and equivalents decreased to $21,947 as of September 30, 2025, from $26,634 as of December 31, 2024, a net decrease of $4,687 [169]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $(6,511), compared to $28,454 provided in 2024 [170]. - Current liabilities increased to $9,815 as of September 30, 2025, from $6,919 as of December 31, 2024, an increase of $2,896 [169]. Product Development and Approvals - The company received European Commission Marketing Authorization for PEDMARQSI® in June 2023, with U.K. approval following in October 2023 [156]. - An exclusive licensing agreement with Norgine was established in March 2024, providing approximately $43,200,000 upfront and potential future milestone and royalty payments of up to $230,000,000 [141]. - PEDMARK® is the first and only FDA- and EMA-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric patients aged one month and older [146]. - The company received Orphan Drug Exclusivity for PEDMARK® in January 2023, granting seven years of market exclusivity until September 20, 2029 [143]. - Norgine plans to launch PEDMARQSI® in Germany and the U.K. in early 2025 [159]. Market Potential - It is estimated that over 10,000 pediatric patients receive platinum-based chemotherapy annually in the U.S. and Europe, with more than 50% potentially suffering permanent hearing loss due to cisplatin [149][155]. - The company has six patents listed for PEDMARK® in the FDA Orange Book, with expiration dates extending to 2039 [143]. Shareholder Information - Outstanding common shares increased to 28,062 as of September 30, 2025, from 27,527 as of December 31, 2024, an increase of 535 shares [174]. - Common shares are recorded as net proceeds after deducting share issuance costs and the fair value of investor warrants, which are recorded as additional paid-in capital [193]. Stock Options and Performance Units - The fair value of stock options is estimated using the Black-Scholes model with a risk-free rate of 3.93-4.19% and expected volatility ranging from 71.04% to 161.67% [191]. - Performance-based units (PSUs) were granted in May and August 2025, with vesting dependent on revenue performance milestones, which are deemed probable as of September 30, 2025 [192].

Core Insights - Fennec Pharmaceuticals reported a record net product sales of $12.5 million for Q3 2025, representing a 79% year-over-year growth, marking the strongest quarter in the company's history [1][8] - The company achieved positive cash flow from operations, with cash and cash equivalents increasing to $22 million as of September 30, 2025 [1][8] - The preliminary results of the clinical trial STS-J01 in Japan are expected in Q4 2025, which could lead to potential registration and partnership opportunities for PEDMARK if results are favorable [1][7] Financial Performance - Net product sales for Q3 2025 were approximately $12.5 million, up from $7.0 million in Q3 2024, indicating significant growth [8][10] - Selling and marketing expenses increased to $5.2 million in Q3 2025 from $4.4 million in Q2 2025 and $4.6 million in Q3 2024 [8] - General and administrative expenses decreased slightly to $6.8 million in Q3 2025 from $7.0 million in Q2 2025 [8] Business Developments - The adoption of PEDMARK has accelerated within key oncology provider networks, reflecting growing confidence in its clinical value [7] - The company is engaged with key opinion leaders and has multiple investigator-initiated studies under review, which are expected to strengthen its clinical and commercial foundation [7] - Fennec's strategy to enhance its commercial organization and drive broader adoption of PEDMARK is showing tangible results [2][7] Upcoming Events - Fennec Pharmaceuticals will host one-on-one investor meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 [4]